Amphiphysin IIm Is Required for Survival of Chlamydia pneumoniae in Macrophages

Elizabeth S. Gold,1 Randi M. Simmons,1 Timothy W. Petersen,1 Lee Ann Campbell,2 Cho-Chou Kuo,2 and Alan Aderem1

1Institute for Systems Biology, Seattle, WA 98103
2Department of Pathobiology, University of Washington, Seattle, WA 98195

Abstract
Macrophages play a critical role in both innate and acquired immunity because of their unique ability to internalize, kill, and degrade bacterial pathogens through the process of phagocytosis. The adaptor protein, amphiphysin IIm, participates in phagocytosis and is transiently associated with early phagosomes. Certain pathogens, including Chlamydia pneumoniae, have evolved mechanisms to subvert macrophage phagosome maturation and, thus, are able to survive within these cells. We report here that, although amphiphysin IIm is usually only transiently associated with the phagosome, it is indefinitely retained on vacuoles containing C. pneumoniae. Under these wild-type conditions, C. pneumoniae do not elicit significant nitric oxide (NO) production and are not killed. Abrogation of amphiphysin IIm function results in C. pneumoniae–induced NO production and in the sterilization of the vacuole. The data suggest that C. pneumoniae retains amphiphysin IIm on the vacuole to survive within the macrophage.

Key words: innate immunity • bacterial infection • pathogen • phagocytosis • nitric oxide

Introduction
Chlamydia pneumoniae are obligate intracellular pathogens that cause multiple types of respiratory tract infections and are responsible for 10% of all cases of community-acquired pneumonia. Exposure to this pathogen is quite common; by age 20 yr, 50% of the population has evidence of past infection (1). C. pneumoniae causes persistent infection in multiple organs and may be associated with several chronic inflammatory conditions, including atherosclerosis (2–4), asthma (5, 6), reactive arthritis (7, 8), and Alzheimer’s disease (9). Interestingly, macrophages are the primary host cell where C. pneumoniae are found in all of these chronic conditions.

Macrophages play a critical role in both innate and acquired immunity because of their unique ability to internalize and degrade bacterial pathogens through the process of phagocytosis. Once internalized, the bacterium is contained in a specialized vacuole known as a phagosome. Phagosomes are dynamic organelles that mature over time through a series of fusion and fission events with vesicles of the endosome/lysosome system. Usually the terminal step in macrophage phagocytosis is the formation of a mature phagolysosome in which the bacterium is killed and processed for eventual presentation to CD4+ T cells. Although it is understood that several bacterial pathogens have evolved strategies to subvert macrophage phagosome maturation and thus evade host defense systems (10), little is known about the mechanism by which this is accomplished.

We have shown previously that a novel adaptor protein, amphiphysin IIm, is required for particle internalization during phagocytosis (11). Amphiphysin IIm binds the GTPase dynamin and recruits it to the nascent phagosome (11). Deletion of the SH3 domain of amphiphysin IIm generates a mutant protein that no longer binds dynamin, and functions as a dominant negative inhibitor of amphiphysin IIm activity (11). Thus, expression of AmphIImSH3– in macrophages prevents the internalization of large particles (>1 μm) by inhibiting membrane extension around the particle.

We report here that, although amphiphysin IIm usually trafficks off phagosomes early in their maturation (~3–5 min after particle binding), it is retained on the C. pneumoniae vacuole for >72 h and its function appears to be a critical factor in the survival of the bacterium.

Address correspondence to Alan Aderem, Institute for Systems Biology, 1441 N. 34th St., Seattle, WA 98103. Phone: (206) 732-1203; Fax: (206) 732-1299; email: aderem@systemsbiology.org

Abbreviations used in this paper: MOI, multiplicity of infection; NO, nitric oxide.
Materials and Methods

DNA Expression Vectors, Cell Lines, and Transformations. Details of the construction of all vectors used in this work have been described previously (11, 12). pTIGZ2 is a bicistronic vector containing a tetracycline-regulated promoter followed by a multiple cloning site, followed by a cap-independent translational enhancer region and the coding region for enhanced GFP. pNeo/Tak was constructed to direct the expression of the tetracycline transactivator under neomycin selection. pTIGZ2-AmphIMH1018 allows for the coexpression of GFP and the dominant negative form of amphiphysin IIIm, in the absence of tetracycline.

The cell line RAW-TT10 is a stable line of RAW 264.7 cells that expresses the tetracycline transactivator. In all experiments in this paper, RAW-TT10 cells were transiently transfected by electroporation. All experiments were performed in the absence of tetracycline to allow for high-level expression of the transfected vectors.

Primary Cells. Murine resident peritoneal macrophages were isolated from CD1 mice (Charles River Laboratories) and cultured as described previously (13). No antibiotics were added to any of the media used in the experiments described in this paper. Bone marrow macrophages were also obtained from CD1 mice. Bone marrow cells were obtained from femurs, plated in Petri dishes in RPMI 1640 with 10% FCS and 20% L-cell media and cultured for 5 d. The macrophages were transferred to glass coverslips and used the next day for experiments.

Bacterial Culture and Infection. C. pneumoniae (strain AR-39) was cultured in HL cells and purified by density gradient centrifugation (Hypaque-76; Winthrop-Breon Laboratories; reference 14). The purified organisms were resuspended in sucrose phosphate glutamic acid and frozen at −70°C until use. Infectivity was determined by direct fluorescent staining of chlamydial inclusions using the FITC-conjugated Chlamydia genus-specific Mab, CF–2 (15). To determine the viability and growth of C. pneumoniae in macrophages, the macrophages were infected at a multiplicity of infection (MOI) of 10:1, the cells were harvested 3 d after the infection and sonicated, and the infectivity titers were assayed in HL cells. Cells were analyzed by confocal microscopy. Inclusions were counted in 25 high-power from three coverslips for each experiment. Data shown represent the average from at least three separate experiments.

The viability of the macrophages before infection was determined by sorting a known number of cells expressing either p-TIGZ2 or pTIGZ2-AmphIMH1018 into 96-well plates. These cells were lifted, and viable cell number was determined by counting cells in the presence of trypan blue. The values expressed are corrected for input cell number.

Immunofluorescence, FACS, and Nitric Oxide (NO) Measurement. The antiamphiphysin IIIm antibody, M8D10, was generated and characterized as described previously (13). M8D10 was detected with either FITC or Texas red anti–rat IgG secondary antibody (Cappel and ICN Biomedicals). Immunofluorescence and FACS staining was performed as described previously (11, 12). Lysine fixable dextran, which has a molecular weight of 10,000, conjugated to Alexa–Fluor 568 (Molecular Probes) was added to macrophages at a concentration of 500 μg/ml for 2 h, the cells were washed, and the dextran was chased into macrophage lysosomes for 24 h before particle loading or infections. Zymosan, Staphylococcus aureus, and Escherichia coli were all labeled with FITC before infections.

Nitrite concentration was measured in supernatant from macrophage cultures using the Griess reagent (Molecular Probes).

Phagocytosis Assays. Full details of the FACS phagocytosis assay and the immunofluorescence procedure have been described previously (12). In this work, 18 h after transfection, RAW-TT10 cells were incubated with the indicated particles (polystyrene “pink” particles; Spherotech, Inc.) for 10 min. The particles were washed off with PBS, and the cells were fixed and analyzed by flow cytometry.

Microscopy was used to confirm that the uninternalized particles were indeed being removed before analysis. RAW-TT10 macrophages were transfected, plated on glass coverslips and, after 18 h, were incubated with biotin–coated polystyrene “pink” fluorescent beads (Spherotech, Inc.). The cells were washed and fixed with formalin. The uninternalized beads were stained with streptavidin conjugated to Cy5 (The Jackson Laboratory). Cells were analyzed on a confocal microscope (Leica).

For the C. pneumoniae internalization assay, RAW-TT10 cells were transfected with the indicated construct. 18 h later, high-expressing cells were sorted onto coverslips using a FACStarPLUS. The cells were allowed to recover for 24 h, were infected with C. pneumoniae at an MOI of 10:1 for 1 h at 37°C. Uninternalized bacteria were removed by incubating the cells in trypsin/EDTA for 10 min at 37°C. The cells were fixed with formalin, permeabilized with 0.25% Triton X-100 in PBS, incubated with primary antibody (CF2 antibody) and with the secondary antibody (anti–mouse TxR; Cappel and ICN Biomedicals), and analyzed by FACS.

Transmission Electron Microscopy. 18 h after transfection, cells expressing high levels of the indicated vectors were sorted into
tissue culture dishes using a FACStarPLUS. The cells were infected for 72 h, fixed with 3% glutaraldehyde (in a 0.1-M cacodylate and 0.1-M sucrose buffer) for 1 h, and rinsed with the cacodylate buffer. Cells were post-fixed for 1 h in 1% OsO$_4$ and dehydrated through a graded ethanol series. They were infiltrated with epoxy resin, polymerized, and cut into 80-nm sections. These were post-stained with 3% uranyl acetate and lead citrate and examined on a Jeol 1200 ExII transmission electron microscope.

Results

Amphiphysin IIm Is Retained on the C. pneumoniae Vacuole.

Certain bacteria, including C. pneumoniae, are able to survive inside the normally hostile environment of a macrophage vacuole (16), and by doing so are able to set up a chronic infection. Therefore, we hypothesized that C. pneumoniae must be able to interfere with normal macrophage phagosome maturation. In fact, although other pathogens localized to dextran positive late phagolysosomes in murine peritoneal and bone marrow macrophages, within hours of internalization, C. pneumoniae were almost never found in this compartment, even 72 h after internalization (Fig. 1 and not depicted).

To identify the mechanism by which C. pneumoniae evades killing by macrophages, we characterized the phenotype of vacuoles containing C. pneumoniae using 150 novel antiphagosomal monoclonal antibodies (13). Using this screen, we found that amphiphysin IIm transiently associated with early phagosomes containing Zymosan, S. aureus, or E. coli was shed from these vacuoles before phagosome–lysosome fusion, and remained absent from these vacuoles indefinitely (Fig. 2, a, b, d, and e and not depicted). In contrast, amphiphysin IIm was retained on the C. pneumoniae vacuole for at least 72 h (Fig. 2, c and f). Because C. pneumoniae survives within its vacuole, the data raised the intriguing possibility that retention of amphiphysin IIm on the C. pneumoniae vacuole kept this vacuole in an immature state.

Macrophages Expressing AmphIImSH3/H11002 Internalize C. pneumoniae Normally but Do Not Allow Their Growth.

To test this hypothesis, we infected macrophages that expressed the...
amphiphysin dominant negative mutant, AmphIImSH3–, in a bicistronic vector with GFP (pTIGZ2 vector). This allowed transiently transfected cells to be identified by their green fluorescence (12, 17). Interestingly, RAW-TT10 macrophages expressing AmphIImSH3– internalized C. pneumoniae normally (Fig. 3, a and b), suggesting that these particles are internalized in a different way to opsonized sheep red blood cells and Zymosan, whose internalization required functional amphiphysin (11). This difference is due to the small size of the bacterium because latex particles of similar size (<0.5 μm) are also internalized in the presence of AmphIImSH3–, whereas larger latex particles are not (Fig. 3 c). Cox et al. have also demonstrated that particle size governs the route of entry into macrophages (18); large particles require the recruitment of new membrane to the forming phagosome to provide the necessary capacity within the vacuole.

We systematically assayed the role of amphiphysin IIm in C. pneumoniae survival in macrophages. RAW-TT10 macrophages expressing the dominant negative form of amphiphysin IIm or empty vector were infected, the cells were lysed, and the lysate was used to infect HL cells; this reinfection step allowed the detection of viable C. pneumoniae recovered from the macrophages. We found that AmphIImSH3– inhibited C. pneumoniae growth in macrophages by 87% (Fig. 4 a). This confirmed our hypothesis that retention of amphiphysin IIm on the C. pneumoniae vacuole is critical for the survival of the bacteria. Transmission electron microscopy demonstrated large numbers of C. pneumoniae contained within vacuoles in control macrophages, whereas cells expressing AmphIImSH3– had vacu-
oles containing remnants of the bacteria with few C. pneumoniae visible (Fig. 4 b). Pretreatment of the cells with L-NMMA, an inhibitor of NO, partially rescued C. pneumoniae survival in AmphImSH3-expressing cells (Fig. 4 a), suggesting that at least some of the killing is due to induction of NO in these cells. Interestingly, C. pneumoniae did not elicit significant NO production from control macrophages, whereas S. aureus and Zymosan did (Fig. 5 a). However, when amphiphysin function was inhibited, the cells produced high levels of NO after infection with C. pneumoniae, and this correlated with sterilization of the vacuole (Fig. 5 a). There was no difference in Zymosan and S. aureus elicited NO production in control cells and cells expressing dominant negative amphiphysin IIm (Fig. 5 a). Although control macrophages did not produce NO in response to C. pneumoniae infection, this was not due to a general inhibition of NO production because these cells produced high levels of NO upon exposure to S. aureus or Zymosan (Fig. 5 b).

**Discussion**

C. pneumoniae are able to establish persistent infections in multiple organ systems and this appears to contribute to several chronic diseases, including atherosclerosis, chronic pulmonary disease, and arthritis (2–8). In all of these conditions, the bacteria are found surviving and replicating in the normally hostile environment of macrophage vacuoles. Therefore, we hypothesized that C. pneumoniae are able to subvert macrophage phagosome maturation, and we show here a role for amphiphysin in this process. We demonstrated previously that amphiphysin IIm is recruited to nascent phagosomes, where it regulates the insertion of membrane (11). Usually, the molecule traffics off phagosomes soon after particle internalization, but in the case of C. pneumoniae it remains on the vacuole indefinitely, and this is critical for the bacteria’s survival.

Amphiphysin has numerous roles in membrane trafficking. Initially, it was shown to be critical in receptor mediated endocytosis; the NH2-terminal domain of amphiphysin interacts with clathrin, whereas its COOH-terminal SH3 domain interacts with the proline-rich domain of dynamin (19, 20). This results in the targeting of dynamin to forming endosomes, which is necessary for scission of the endosome from the plasma membrane (21). More recent work has demonstrated that amphiphysin also has roles in exocytosis (22, 23) and intracellular vesicular trafficking (24). Amphiphysin also appears to have a direct effect on membrane deformation and curvature (25, 26). In addition to its general role in regulating membrane traffic, we and others have also demonstrated that amphiphysin has a role in phagosome maturation by controlling membrane insertion into the forming phagosome (11, 27). This function of the molecule appears to be related to its capacity to activate dynamin and recruit PI-3 kinase (11). In turn, PI-3 kinase has a central role in regulating membrane traffic (28). Thus the role for amphiphysin in membrane traffic is unequivocal, and it is reasonable to postulate that its capture on the immature phagosome is the underlying reason why the chlamydial vacuole does not progress to a fully fledged phagolysosome where effective killing of the bacterium can occur.

It has been demonstrated recently that a related Chlamydia species, *Chlamydia trachomatis*, is able to survive in macrophages and that this was reversed by the activation of phospholipase D (29). Amphiphysin is known to bind directly to phospholipase D and inhibit its activity by doing so (30); it is possible that by retaining amphiphysin on its vacuole, C. pneumoniae may inhibit phospholipase D activity and promote its own survival.

The precise mechanism by which amphiphysin prevents chlamydial killing is not fully elucidated, but it does appear to involve the induction of inducible NO synthase. Macrophage production of NO is known to play a key role in host defense against a wide variety of pathogens including *Mycobacterium tuberculosis*, *Leishmania major*, *Listeria monocytogenes*, and *Tetoxoplasma gondii* (31). NO also has an important role in control of *C. pneumoniae* infection as evidenced by the observation that inducible NO synthase−/− mice have increased susceptibility to respiratory infection with these bacteria (32), and are more susceptible to *C. pneumoniae* induced exacerbation of atherosclerotic lesions (33).

We demonstrate here that macrophages produce very little NO when they internalize *C. pneumoniae*. However, when amphiphysin function is abrogated, *C. pneumoniae* provokes robust NO production and this correlates with sterilization of the vacuole. *C. pneumoniae* does not globally disable the machinery necessary for NO production, as infected macrophages are still able to produce NO when exposed to a second stimulus.

Together, our data suggest that by retaining functional amphiphysin IIm on the vacuole, *C. pneumoniae* are able to prevent vacuole maturation, thereby avoiding the detection mechanisms that activate NO production.

E.S. Gold is supported by a National Heart, Blood, and Lung Institute grant (no. 5K08HL071582-02). L. Campbell is supported by a United States Public Health Service (USPHS) grant (no. AI43060). C-C. Kuo is supported by a USPHS grant (no. AI43060). A. Ademi is supported by National Institute of Allergy and Infectious Diseases grants (nos. R37 AI25032, R01 AI32972, R01 AI52286, and U54 AI54523).

The authors have no conflicting financial interests.

Submitted: 22 March 2004
Accepted: 13 July 2004

**References**

1. Kuo, C.C., L.A. Jackson, L.A. Campbell, and J.T. Grayston. 1995. Chlamydia pneumoniae (TWAR). *Clin. Microbiol. Rev.* 8:451–461.
2. Thom, D.H., J.T. Grayston, D.S. Siscovick, S.P. Wang, N.S. Weiss, and J.R. Daling. 1992. Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. *JAMA.* 268:68–72.
3. Muhlestein, J.B., E.H. Hammond, J.F. Carlquist, E. Radicke, M.J. Thomson, L.A. Karagounis, M.L. Woods, and J.L. Anderson. 1996. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J. Am. Coll. Cardiol. 27:1555–1561.

4. Muhlestein, J.B., J.L. Anderson, E.H. Hammond, L. Zhao, S. Trehan, E.P. Schwobe, and J.F. Carlquist. 1998. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation. 97:633–636.

5. von, H.L. 2002. Role of persistent infection in the control and severity of asthma: focus on Chlamydia pneumoniae. Eur. Respir. J. 19:546–556.

6. Gencay, M., J.J. Rudiger, M. Tamm, M. Soler, A.P. Perruchoud, and M. Roth. 2001. Increased frequency of Chlamydia pneumoniae antibodies in patients with asthma. Am. J. Respir. Crit. Care Med. 163:1097–1100.

7. Villareal, C., J.A. Whittum-Hudson, and A.P. Hudson. 2002. Persistent Chlamydiae and chronic arthritis. Arthritis Res. 4:5–9.

8. Hannu, T., M. Puolakkainen, and M. Leirisalo-Repo. 1999. Identification of a new group of Chlamydia psittaci strains TWAR. J. Clin. Microbiol. 37:285–292.

9. Balin, B.J., H.C. Gerard, E.J. Arking, D.M. Appelt, P.J. McNiven, and A. Aderem. 1999. Dynamin 2 is required for macropage phagocytes. J. Exp. Med. 190:1–8.

10. Gold, E.S., N.S. Morrissette, D.M. Underhill, J. Guo, M. Bassetti, and A. Aderem. 2000. Amphiphysin IIm, a novel amphiphysin II isoform, is required for macrophage phagocytes. Immunity. 12:285–292.

11. Gold, E.S., D.M. Underhill, N.S. Morrissette, J. Guo, M.A. McNiven, and A. Aderem. 1999. Dynamin 2 is required for phagocytes in macrophages. J. Exp. Med. 190:1–8.

12. Morrissette, N.S., E.S. Gold, J. Guo, J.A. Hameman, A. Ozinsky, V. Bedian, and A.A. Aderem. 1999. Isolation and characterization of monoclonal antibodies directed against novel components of macrophage phagosomes. J. Cell Sci. 112:4705–4713.

13. Kuo, C.C., and J.T. Grayston. 1990. A sensitive cell line, HL cells, for isolation and propagation of Chlamydia pneumonia strain TWAR. J. Infect. Dis. 162:755–758.

14. Kuo, C.C., H.H. Chen, S.P. Wang, and J.T. Grayston. 1986. Identification of a new group of Chlamydia psittaci strains called TWAR. J. Clin. Microbiol. 24:1034–1037.

15. Godzik, K.L., E.R. O’Brien, S.K. Wang, and C.C. Kuo. 1995. In vitro susceptibility of human vascular wall cells to infection with Chlamydia pneumoniae. J. Clin. Microbiol. 33:2411–2414.

16. Underhill, D.M., A. Ozinsky, A.M. Hajjar, A. Stevens, C.B. Wilson, M. Bassetti, and A. Aderem. 1999. The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature. 401:811–815.